Roche, Nurix Therapeutics $2.3B Bexobrutideg Deal

Roche has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to co-develop and co-commercialize bexobrutideg (also known as NX-5948), an investigational Bruton's Tyrosine Kinase (BTK) degrader. Roche will pay Nurix Therapeutics an upfront cash payment of over $700 million, with potential milestone payments reaching up to $2.3 billion. The agreement outlines a shared development cost structure, with Roche covering 60% and Nurix Therapeutics 40%. In the US, profits and losses from commercialization will be split equally, while Roche will handle commercialization outside the US, with Nurix Therapeutics receiving royalties. Bexobrutideg is an orally bioavailable, brain-penetrant BTK degrader that eliminates the BTK protein from cells, offering a potential advantage over conventional BTK inhibitors by overcoming resistance mechanisms. A Phase III clinical trial for bexobrutideg in second-line chronic lymphocytic leukemia (CLL) is planned for summer 2026. The collaboration expands Roche's hematology portfolio and opens new therapeutic avenues in immunology and neurology, where BTK is a relevant target. For Nurix Therapeutics, the partnership provides global development infrastructure and commercial reach.